Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
Tài liệu tham khảo
Stroes, 2015, Statin-associated muscle symptoms: impact on statin therapy-european atherosclerosis society consensus panel statement on assessment, aetiology and management, Eur. Heart J., 36, 1012, 10.1093/eurheartj/ehv043
Kashani, 2006, Risks associated with statin therapy: a systematic overview of randomized clinical trials, Circulation, 114, 2788, 10.1161/CIRCULATIONAHA.106.624890
Law, 2006, Statin safety: a systematic review, Am. J. Cardiol., 97, 52C, 10.1016/j.amjcard.2005.12.010
Naci, 2013, Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials, Circ Cardiovasc Qual Outcomes, 6, 390, 10.1161/CIRCOUTCOMES.111.000071
Bruckert, 2005, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study, Cardiovasc. Drugs Ther., 19, 403, 10.1007/s10557-005-5686-z
Cohen, 2012, Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users, J Clin Lipidol, 6, 208, 10.1016/j.jacl.2012.03.003
Zhang, 2013, Discontinuation of statins in routine care settings: a cohort study, Ann. Intern. Med., 158, 526, 10.7326/0003-4819-158-7-201304020-00004
Serban, 2017, Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction, J. Am. Coll. Cardiol., 69, 1386, 10.1016/j.jacc.2016.12.036
Rosenson, 2017, Optimizing cholesterol treatment in patients with muscle complaints, J. Am. Coll. Cardiol., 70, 1290, 10.1016/j.jacc.2017.07.752
Toth, 2018, Management of statin intolerance in 2018: still more questions than answers, Am. J. Cardiovasc. Drugs, 10.1007/s40256-017-0259-7
Penson, 2017, Evaluating bempedoic acid for the treatment of hyperlipidaemia, Expet Opin. Invest. Drugs, 26, 251, 10.1080/13543784.2017.1280458
Gutierrez, 2014, Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus, Arterioscler. Thromb. Vasc. Biol., 34, 676, 10.1161/ATVBAHA.113.302677
Thompson, 2015, Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance, J Clin Lipidol, 9, 295, 10.1016/j.jacl.2015.03.003
Thompson, 2016, Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance, J Clin Lipidol, 10, 556, 10.1016/j.jacl.2015.12.025
Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129, S1, 10.1161/01.cir.0000437738.63853.7a
Buckley, 2009, C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force, Ann. Intern. Med., 151, 483, 10.7326/0003-4819-151-7-200910060-00009
Ridker, 2010, Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), Am. J. Cardiol., 106, 204, 10.1016/j.amjcard.2010.03.018
Puri, 2013, C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy, Circulation, 128, 2395, 10.1161/CIRCULATIONAHA.113.004243
Li, 2017, Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis, Atherosclerosis, 259, 75, 10.1016/j.atherosclerosis.2017.02.003
Ridker, 2017, Antiinflammatory therapy with canakinumab for atherosclerotic disease, N. Engl. J. Med., 377, 1119, 10.1056/NEJMoa1707914